NCT04923854 Phenotypic Exploration of Autism Spectrum Disorders Retrospective and Prospective Data
| NCT ID | NCT04923854 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Autism Spectrum Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2021-07-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2021-07-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autism Spectrum Disorders (ASD) are a heterogeneous group of severe developmental abnormalities of the nervous system characterized by deficits in social interaction and verbal and nonverbal communication affecting approximately 1% of the general population. In 5-40% of cases, genetic factors are identified as the cause of these disorders. Despite this unique definition and the advancement of techniques, ASD is still a clinically and genetically heterogeneous condition, as several hundred genes have been identified to date. Primary Objective and Endpoint Primary Objective: Exploration of phenotypic heterogeneity in patients with ASD. Primary endpoint: * Routine Care Clinical Investigation Criteria. * Scores on assessment scales,
Eligibility Criteria
Inclusion Criteria: * child (age \<18 years) with Autism Spectrum DisorderAutism Spectrum Disorder Exclusion Criteria: \-
Contact & Investigator
Richard DELORME, PhD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT04923854 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 18 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04923854 currently recruiting?
Yes, NCT04923854 is actively recruiting participants. Contact the research team at anna.maruani@aphp.fr for enrollment information.
Where is the NCT04923854 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT04923854 clinical trial?
NCT04923854 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Richard DELORME, PhD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 1,500 participants.